Pharmagreen Biotech Inc.

Equities

PHBI

US71716C1099

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 11:16:19 2024-05-08 am EDT			5-day change	1st Jan Change
0.0008 ^USD	-11.11%		+14.29%	+33.33%

Feb. 21	Pharmagreen Biotech Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	CI
Jan. 09	Pharmagreen Biotech Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	CI

PHARMAGREEN BIOTECH INC. : Other Events (form 8-K)

October 20, 2020 at 06:04 am EDT

Item 8.01 Other Events.

On October 19, 2020, Pharmagreen Biotech Inc. announced that it is no longer under chapter 11 proceedings of the U.S. Bankruptcy Code. On August 11, 2020, the Company voluntarily filed for petitions for relief under chapter 11. On October 09, 2020, a stay order was lifted by a United States District Judge of the United States District Court for the Southern District of New York, on an action filed by EMA Financial LLC. The company does not plan to appeal this ruling. This effectively removed the company from its Chapter 11 bankruptcy proceedings and protection.

Latest news about Pharmagreen Biotech Inc.

Pharmagreen Biotech Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 20	CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	Jan. 08	CI
Pharmagreen Biotech Inc. cancelled the transaction announced on November 2, 2022	Nov. 01	CI
Pharmagreen Starts Sales of MaxGenomicTM Supplement on Amazon.Com and Develops Its Next Pre-Workout Formulation	23-09-05	CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-14	CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-05-19	CI
Pharmagreen Biotech Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	23-02-14	CI
Pharmagreen Biotech, Inc. Launches Online Sales for Its MaxGenomic(TM) Supplement Product	23-02-08	CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Full Year Ended September 30, 2022	23-01-17	CI
Pharmagreen Biotech Inc. Auditor Raises 'Going Concern' Doubt	23-01-16	CI
Pharmagreen Biotech Inc. announced that it expects to receive $0.05 million in funding from JanBella Group, LLC	22-11-01	CI
Pharmagreen Biotech Inc. Develops a Proprietary Nutraceutical Formulation and Prepares for Product Launch	22-09-08	CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022	22-08-17	CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022	22-05-16	CI
Pharmagreen Biotech Inc. Reports Earnings Results for the First Quarter Ended December 31, 2021	22-02-22	CI
Pharmagreen Biotech Inc. completed the acquisition of Long Valley Farms LLC.	22-01-19	CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Full Year Ended September 30, 2021	21-12-29	CI
Pharmagreen Biotech Inc. Auditor Raises 'Going Concern' Doubt	21-12-28	CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Third Quarter Ended June 30, 2021	21-08-18	CI
Pharmagreen Biotech Inc. entered into memorandum of understanding to acquire Long Valley Farms LLC for $2.4 million.	21-08-11	CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Second Quarter Ended March 31, 2021	21-05-24	CI
Pharmagreen Biotech Inc. Signs LOI to Supply Crude CBD Oil Extracted from Certified Organically Grown Hemp Biomass	21-02-16	CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Full Year Ended September 30, 2020	21-01-08	CI
Pharmagreen Biotech Inc. announced a financing transaction	20-10-13	CI
Pharmagreen Biotech Inc. Reports Earnings Results for the Third Quarter Ended June 30, 2020	20-08-19	CI

Chart Pharmagreen Biotech Inc.

Duration

Period

More charts

Company Profile

Pharmagreen Biotech, Inc. is a Canada-based company. The Company is engaged in developing its line of nutraceutical products, which is a blend of therapeutic plants and mushrooms. Utilizing the Company's expertise in plant genetics, its transgenic program uses the technology available to research and create nutraceuticals, and daily supplements with the potential to improve lives and address a wide variety of ailing conditions. Its nutraceutical product, MaxGenomic Supplement, comes in a bottle with 60 enteric capsules. The MaxGenomic Supplement is a proprietary blend that consists of nine medicinal mushrooms and six medical plants to help support the human mind and body. Its other nutraceutical products are in various development stages. Its subsidiaries include WFS Pharmagreen Inc, and 1155097 BC Ltd.

Sector

Biotechnology & Medical Research

Calendar

2024-05-20 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PHARMAGREEN BIOTECH INC.	+33.33%	531K
MODERNA, INC.	+22.56%	46.71B
IQVIA HOLDINGS INC.	-1.51%	41.52B
LONZA GROUP AG	+48.83%	41.8B
CELLTRION, INC.	-3.42%	29.55B
ICON PUBLIC LIMITED COMPANY	+10.13%	25.78B
ALNYLAM PHARMACEUTICALS, INC.	-20.44%	19.26B
MEDPACE HOLDINGS, INC.	+26.45%	11.98B
BIO-TECHNE CORPORATION	-0.14%	12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.47%	12.08B

Other Biotechnology & Medical Research